riluzole and Chronic Motor and Vocal Tic Disorder

riluzole has been researched along with Chronic Motor and Vocal Tic Disorder in 2 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Research

Studies (2)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Improvement in OCD Severity

Childrens' Yale-Brown Obsessive-Compulsive Scale (CY-BOCS). 10-item scale. Each item is rated from 0-4. A sum total is calculated by adding items 1-10. 0-7: Subclinical. 8-15: Mild. 16-23: Moderate. 24-31: Severe. 32-40: Extreme. (NCT01172288)
Timeframe: 12 weeks

Improvement in Tic Severity

"Yale Global Tic Severity Scale is a standard psychiatric measure that rates tics from 0 (no tics) to 100 (most severe tics).~It separately rates motor tics and vocal tics in 5 subscales (number, frequency, intensity, complexity and interference) where the maximum severity score for motor tics is 25 and for vocal tics is 25. Giving us the Total Tic Severity Score maximum of 50.~The additional Impairment Scale rates the degree of disability caused by the tics ranging from 0 (none) to 50 (severe). When these two scores are added we get the Yale Global Tic Severity Scale Score." (NCT01172288)
Timeframe: 12 weeks

Improvement of Premonitory Urges

"Premonitory Urge for Tics Scale (PUTS). Items are rated on a scale of 1-4 from least to most. A total score is calculated by summing the scores of all items. Nine is the minimum possible score. A score of 12.5-24.5 indicates medium intensity of premonitory urges for tics. A score of 25-30.5 indicates high intensity which may be associated with marked impairment. Scores 31 and above indicate extremely high intensity with probable severe impairment. A score of 36 is the maximum score possible." (NCT01172288)
Timeframe: 12 weeks

Overall Improvement

Clinical Global Impression - Improvement Scale (CGI-I). The CGI is a 7-point scare that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. (NCT01172288)
Timeframe: 12 weeks

Number of Participants With Adverse Effects

Number of participants with adverse events according to the Pediatric Adverse Events Rating Scale (NCT01172288)
Timeframe: 12 weeks

Trials

1 trial available for riluzole and Chronic Motor and Vocal Tic Disorder

Other Studies

1 other study available for riluzole and Chronic Motor and Vocal Tic Disorder